ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these areas.

Colorectal Cancer

Dung T. Le, MD, and Axel Grothey, MD

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).

Issues in Oncology

Lee S. Schwartzberg, MD

Lee S. Schwartzberg, MD, on ICLIO: Adopting Immunotherapy in the Community Setting

Lee S. Schwartzberg, MD, of The West Clinic, describes a new initiative of the Association of Community Cancer Centers, designed to speed the adoption of immunotherapeutics in the community setting, where 60% of cancer patients are treated.

Lymphoma

Andrew Zelenetz, MD, PhD

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses two important lymphoma trials presented at ASCO and his views on whether their results are indeed practice-changing (Abstract 8504 and LBA8502).

Supportive Care

Symptom Management

Palliative Care

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).

Sep

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

Lee S. Schwartzberg, MD, on ICLIO: Adopting Immunotherapy in the Community Setting

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC

Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes

Duane Mitchell Named Director of the UF Health Cancer Institute

Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer

FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer